CRT 2026

CHANGES IN GOVERNMENT ENVIRONMENT | IMPACT ON CARDIOVASCULAR TRANSLATIONAL RESEARCH

Moderator(s)

• 

  Charles A. Simonton, MD, FACC, FSCAI

  EVP Chief Medical Officer
  Abiomed a Johnson + Johnson MedTech Company
  Charlotte, North Carolina, United States

  Disclosure information not submitted.
• 

  Spencer B. King, III, MD, MACC, MSCAI

  Professor of Medicine Emeritus
  Emory University
  Atlanta, Georgia, United States

  Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

• 

  Nabil Dib, MD, MSc, FACC

  Director Cardiovascular Research
  Mercy Gilbert Medical Center/Dignity Health
  Gilbert, Arizona, United States

  Disclosure(s): No financial relationships to disclose
• 

  Bram Zuckerman, MD

  Director Office of CV Devices
  U.S. Food and Drug Administration
  Silver Spring, Maryland, United States

  Disclosure information not submitted.